Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 4/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL717332 | 0.81 | SLC6A2 (0.39) | NR3C1HSD17B2HTR7HTR1AALOX5 | |
| SCHEMBL7836983 | 0.76 | HTR2A (0.62) | HTR7HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12437837 | 0.71 | CYP2A6 (0.52) | HTR7HTR1AALOX5SLC6A2SLC6A4 | |
| SCHEMBL25462183 | 0.71 | ALOX5 (0.51) | HSD17B2HTR7HTR1AALOX5SLC6A2 | |
| SCHEMBL2967148 | 0.71 | ALOX5 (0.55) | NR3C1HSD17B2HTR7HTR1AALOX5 | |
| SCHEMBL1095514 | 0.71 | ALOX5 (0.55) | NR3C1HSD17B2HTR7HTR1AALOX5 | |
| Hydrochloric Acid SCHEMBL2321691 | 0.70 | CYP2A6 (0.50) | HTR7HTR1AALOX5SLC6A2SLC6A4 | |
| SCHEMBL716779 | 0.70 | IDO1 (0.39) | LMNA | |
| SCHEMBL720511 | 0.70 | IDO1 (0.36) | LMNA | |
| SCHEMBL8036927 | 0.69 | GABRA1 (0.42) | LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436043-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-07 | — | — | US | disclosed |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
| EP-2251326-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NR3C1 436/4885HSD17B2 267/4885HTR7 2544/4885 |
| US-20120270865-A2 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | NR3C1 436/4885HSD17B2 267/4885HTR7 2544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.